Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from PBMs

The inescapable ad campaign for a wonky drug policy debate - Roll Call

A seven-figure, yearlong PhRMA ad campaign has taken a very wonky policy debate mainstream — and it's made a longtime actor a familiar face.

Roll Call

Lawmakers Crackdown on Pharmacy Benefit Managers: The Kiplinger Letter

A crackdown on pharmacy benefit managers on drug costs might help Congress forget their differences.

Kiplinger

Howard Dean: 'At last, Congress proposes drug pricing reform that works'

The Patients Before Middlemen Act strikes at the heart of what makes prescription drugs so unaffordable in the U.S., according to Howard Dean.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

What you need to know about the drug price fight in those TV ads

In recent months ominous ads about prescription drugs have flooded the TV airwaves. Perhaps by design, it’s not always clear who’s sponsoring the ads or why.

Tribune News Service

What to know about the drug price fight in those TV ads

At least nine bills introduced in Congress take aim at pharmacy benefit managers, the powerful middlemen that channel prescription drugs to patients. Here's what the fuss is all about.

WEKU

Will lower-cost Humira pharmaceutical options soon be available to patients?

Seven new alternatives to the high-cost Humira drug will be available in July. Some will be offered at significantly lower prices, but will patients see big savings?

Tribune News Service

Humira, the world’s top-selling drug, faces an upcoming test from low cost alternatives

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

A more aggressive FTC is starting to target drug mergers and industry middlemen

Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration’s push for lower drug prices at the pharmacy counter.

Tribune News Service

House, Senate craft separate health care packages - Roll Call

A deal announced this week on a series of drug pricing bills could be a sign of progress an issue that has bedeviled both parties.

Roll Call

Patient Privacy at Risk in Senate Bill Aimed at Pharmacy Managers

Prosecutors could end up with a trove of patient-level data regarding highly personal drugs like Viagra, abortion pills, and more.

Reason

Michael Hiltzik: Eli Lilly is slashing insulin prices, but hold your applause

Eli Lilly & Co. played the altruism card like a champ on Mar. 1, when it announced steep price cuts on its insulin products of as much as 70%.

Los Angeles Times

After capping insulin copays, Colorado sets its sights on EpiPens

Almost four years after becoming the first state to cap insulin copayments, Colorado may limit what consumers pay for epinephrine autoinjectors, also known as EpiPens, which treat serious allergic reactions.

Tribune News Service

After capping the price of insulin, Colorado sets its sights on EpiPen copays

Colorado’s proposed legislation to cap EpiPen copays is part of a nationwide effort against skyrocketing drug prices.

Fortune

Mark Cuban has been taking on the drug industry. But which one?

The billionaire entrepreneur is making waves with his new drug company. But his generics aren’t always the lowest-priced deal.

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

Tribune News Service

Drug company middlemen likely to be a focus in 118th Congress

WASHINGTON — Factions of the health care system and members of Congress are turning their fire on an oft-maligned part of the drug pricing system — the middlemen who negotiate discounts with drug companies on behalf of health plans.

Roll Call

Drug company middlemen likely to be a focus in 118th Congress - Roll Call

PBMs argue that the rebates they collect from drug companies in exchange for coverage by a health plan are used to lower premiums.

The Independent UK

Can billionaire celebrity Mark Cuban fix America’s broken health system?

The celebrity investor has teamed up with a soft-spoken radiologist to tackle the USA’s healthcare crisis – and he has drug industry middlemen squarely in his sights, reports Io Dodds

Chicago Tribune

Commentary: It’s time to crack down on the middlemen that inflate the costs of drugs like insulin

U.S. Sen. Raphael Warnock just introduced a bill that would cap Americans’ out-of-pocket spending on insulin at $35 a month. The legislation would be a godsend to patients battling diabetes. Many of them currently face hundreds of dollars in monthly out-of-pocket costs — an unaffordable burden for many low- and…

Get all your
news in one place.

100's of premium titles.
One news app.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

The Federal Trade Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.